The active substance is more than 99% bound to protein in the blood. As a result of reactions occurring in the body, tamoxifen breaks down into a number of metabolites, which are similar in structure to the starting material. This is what contributes to the achievement of a sustainable therapeutic effect.
Withdrawal of the drug from the body occurs with the help of the intestines and kidneys. Most are excreted in the form of metabolites with feces.
Interaction with other drugs
The use of the drug simultaneously with anticoagulants derived from coumarin enhances the anticoagulant effect. Therefore, simultaneous administration should be carried out exclusively under the close supervision of the attending physician.
The complex use of the drug with allopurinol causes a hepatotoxic effect.
When taken with drugs containing tamoxifen, atracuria causes a prolongation of neuromuscular blockade.
It causes an increase in the dopaminergic effect of bromocriptine when used with bromocriptine.
Side effects are possible, such as prolonging prothrombin time, hematoma, hematuria while taking Tamoxifen and drugs containing tamoxifen.
It is also possible the development of hemolytic uremic syndrome with the use of drugs and mitomycin.
Tamoxifen is available in the form of flat tablets of a square shape, the color of which varies from white with a yellow tint to cream. The edges of the drug are rounded, along the perimeter there is a chamfer. On one side there is a risk and engraving "BP".
Tamoxifen should be stored at a temperature of at least + 15 ° C and no more than + 25 ° C, out of the reach of children. Avoid exposure to ultraviolet rays, which have a destructive effect on the product.
The shelf life of the drug Tamoxifen 5 years.
After the expiration date indicated on the package, the use of Tamoxifen is not recommended.
When taking the medicine, driving and other vehicles is prohibited, as well as working with dangerous mechanisms that require increased concentration, attention and reaction.
During the course of treatment, it is necessary to constantly monitor the level of platelets and leukocytes in the blood, the level of calcium in the body, as well as the rate of blood coagulation, since the development of thrombocytopenia or leukopenia is possible.
The medication is ineffective in the treatment of malignant tumors with liver metastases.
In women who are in the premenopausal period, who are undergoing Tamoxifen therapy for the treatment of a malignant tumor of the breast, menstrual irregularities or lack of menstruation can be observed.
In combination with alcohol, the drug is strictly prohibited.